EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fumagillin inhibits growth of the enteric protozoan parasite Entamoeba histolytica by covalently binding to and selectively inhibiting methionine aminopeptidase 2

Natsuki Watanabe iD, Yumiko Saito-Nakano iD, Naoaki Kurisawa, Keisuke Otomo, Kiyotake Suenaga, Kentaro Nakano, Tomoyoshi Nozaki iD

Antimicrobial Agents and Chemotherapy · 2023

DOI: 10.1128/aac.00560-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Natsuki Watanabe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo , Tokyo, Japan. Hauptthemen laut MEDLINE: Entamoeba histolytica, Parasites, Amebiasis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science (JSPS), Japan Agency for Medical Research and Development (AMED).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amebiasis is an important cause of morbidity and mortality worldwide, and caused by infection with the protozoan parasite Entamoeba histolytica . Metronidazole is currently the first-line drug despite adverse effects and concerns on the emergence of drug resistance. Fumagillin, a fungal metabolite from Aspergillus fumigatus, and its structurally related natural and synthetic compounds have been previously explored as potential anti-angiogenesis inhibitors for cancers, anti-microbial, and anti-obese compounds. Although fumagillin was used for human amebiasis in clinical trials in 1950s, the mode of action of fumagillin remains elusive until now. In this report, we showed that fumagillin covalently binds to methionine aminopeptidase 2 (MetAP2) and non-covalently but abundantly binds to patatin family phospholipase A (PLA). Susceptibility against fumagillin of the amebic strains in which expression of E. histolytica MetAP2 ( EhMetAP2 ) gene was silenced increased compared to control strain. Conversely, overexpression of EhMetAP2 mutants that harbors amino acid substitutions responsible for resistance to ovalicin, a fumagillin analog, in human MetAP2, also resulted in decrease in fumagillin susceptibility. In contrast, neither gene silencing nor overexpression of E. histolytica PLA (EhPLA) affected fumagillin susceptibility. These data suggest that EhPLA is not essential and not the target of fumagillin for its amebicidal activity. Taken together, our data have demonstrated that EhMetAP2 is the primary target for amebicidal activity of fumagillin, and EhMetAP2 represents a rational explorable target for the development of alternative therapeutic agents against amebiasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Entamoeba histolyticaParasitesAmebiasisAnimalsHumansPolyestersAminopeptidasesMetalloendopeptidasesCyclohexanesFatty Acids, UnsaturatedSesquiterpenes

Stichwörter der Autor:innen

Entamoeba histolyticafumagillinmethionine aminopeptidase 2patatin family

Substanzen

Polyestersmethionine aminopeptidase 2AminopeptidasesMetalloendopeptidasesfumagillinCyclohexanesFatty Acids, UnsaturatedSesquiterpenes

Autor:innen und Institutionen

  • Department of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo , Tokyo, Japan.
  • Department of Parasitology and Antimicrobial Resistance Research Center, National Institute of Infectious Diseases , Tokyo, Japan.
  • Department of Chemistry, Faculty of Science and Technology, Keio University , Kanagawa, Japan.
  • Degree Programs in Biology, Graduate School of Science and Technology, University of Tsukuba , Ibaraki, Japan.

ORCID-Profile: Natsuki Watanabe, Yumiko Saito-Nakano, Tomoyoshi Nozaki

Förderung

  • MEXT | Japan Society for the Promotion of Science (JSPS)
  • Japan Agency for Medical Research and Development (AMED)

Zitieren

APA

Watanabe, N., Saito-Nakano, Y., Kurisawa, N., Otomo, K., Suenaga, K., Nakano, K., & Nozaki, T. (2023). Fumagillin inhibits growth of the enteric protozoan parasite Entamoeba histolytica by covalently binding to and selectively inhibiting methionine aminopeptidase 2. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00560-23

Vancouver

Watanabe N, Saito-Nakano Y, Kurisawa N, Otomo K, Suenaga K, Nakano K, et al. Fumagillin inhibits growth of the enteric protozoan parasite Entamoeba histolytica by covalently binding to and selectively inhibiting methionine aminopeptidase 2. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00560-23

BibTeX
@article{Watanabe2023,
  author = {Watanabe, Natsuki and Saito-Nakano, Yumiko and Kurisawa, Naoaki and Otomo, Keisuke and Suenaga, Kiyotake and Nakano, Kentaro and Nozaki, Tomoyoshi},
  title = {Fumagillin inhibits growth of the enteric protozoan parasite Entamoeba histolytica by covalently binding to and selectively inhibiting methionine aminopeptidase 2},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  doi = {10.1128/aac.00560-23}
}
Kostenlos starten →